Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma

CD19 chimeric antigen receptor T-cell (CAR-T) therapy is efficacious for refractory/relapsed (R/R) B-cell hematological malignancies, yet relapse due to CD19 antigen escape remains a challenge. Our trial explored simultaneous targeting of multiple B-cell antigens as a therapeutic approach that may r...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Lefu, Li, Jingjing, Yang, Junfang, Zhang, Xian, Zhang, Min, He, Jiujiang, Zhang, Gailing, Li, Wenqian, Wang, Hui, Li, Jianqiang, Lu, Peihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776474/
https://www.ncbi.nlm.nih.gov/pubmed/36552849
http://dx.doi.org/10.3390/cells11244085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776474/
https://www.ncbi.nlm.nih.gov/pubmed/36552849
http://dx.doi.org/10.3390/cells11244085

Ejemplares similares